Glioma Vaccine Shows Early Signs of Success

    Cancer Discovery
    |May 5, 2021
    PubMed

    A vaccine targeting IDH1 in patients with newly diagnosed diffuse glioma may be worth pursuing, researchers say. In a phase I trial, the vaccine was deemed safe, and it induced an immune response-including clonal expansion of CD4 T cells-in 93.3% of patients.

    Related Concept Videos